Recent Finacing
Recent Raise
Spyryx Biosciences develops ENaC-inhibiting therapeutics that mimic SPLUNC1 for cystic fibrosis and COPD, conducting lead selection and preparing pre‑IND activities from Research Triangle Park.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors